271 related articles for article (PubMed ID: 36771113)
1. Could Naringenin Participate as a Regulator of Obesity and Satiety?
López-Almada G; Domínguez-Avila JA; Mejía-León ME; Robles-Sánchez M; González-Aguilar GA; Salazar-López NJ
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771113
[TBL] [Abstract][Full Text] [Related]
2. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
3. Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.
Assini JM; Mulvihill EE; Burke AC; Sutherland BG; Telford DE; Chhoker SS; Sawyez CG; Drangova M; Adams AC; Kharitonenkov A; Pin CL; Huff MW
Endocrinology; 2015 Jun; 156(6):2087-102. PubMed ID: 25774553
[TBL] [Abstract][Full Text] [Related]
4. Naringenin suppresses neutrophil infiltration into adipose tissue in high-fat diet-induced obese mice.
Tsuhako R; Yoshida H; Sugita C; Kurokawa M
J Nat Med; 2020 Jan; 74(1):229-237. PubMed ID: 31218550
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease.
Naeini F; Namkhah Z; Ostadrahimi A; Tutunchi H; Hosseinzadeh-Attar MJ
Adv Nutr; 2021 Mar; 12(2):413-428. PubMed ID: 32879962
[TBL] [Abstract][Full Text] [Related]
7. Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis.
Mulvihill EE; Burke AC; Huff MW
Annu Rev Nutr; 2016 Jul; 36():275-99. PubMed ID: 27146015
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.
Rosso C; Kazankov K; Younes R; Esmaili S; Marietti M; Sacco M; Carli F; Gaggini M; Salomone F; Møller HJ; Abate ML; Vilstrup H; Gastaldelli A; George J; Grønbæk H; Bugianesi E
J Hepatol; 2019 Nov; 71(5):1012-1021. PubMed ID: 31301321
[TBL] [Abstract][Full Text] [Related]
9. Dietary Eriodictyol Alleviates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obese Mice.
Kwon EY; Choi MS
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862092
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Naringenin-loaded nanoparticles for targeting of Vanin-1, iNOS, and MCP-1 signaling pathway in HFD-induced obesity.
Salah A; Mohammed El-Laban N; Mafiz Alam S; Shahidul Islam M; Abdalla Hussein M; Roshdy T
Int J Pharm; 2024 Apr; 654():123967. PubMed ID: 38438083
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic Properties of Naringenin: A Citrus Fruit Polyphenol.
Den Hartogh DJ; Tsiani E
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30871083
[TBL] [Abstract][Full Text] [Related]
12. Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.
Assini JM; Mulvihill EE; Sutherland BG; Telford DE; Sawyez CG; Felder SL; Chhoker S; Edwards JY; Gros R; Huff MW
J Lipid Res; 2013 Mar; 54(3):711-724. PubMed ID: 23269394
[TBL] [Abstract][Full Text] [Related]
13. [Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker].
Chellali S; Boudiba A; Griene L; Koceir EA
Ann Biol Clin (Paris); 2019 Jun; 77(3):261-271. PubMed ID: 30998190
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of citrus flavanones on hepatic gluconeogenesis.
Constantin RP; Constantin RP; Bracht A; Yamamoto NS; Ishii-Iwamoto EL; Constantin J
Fitoterapia; 2014 Jan; 92():148-62. PubMed ID: 24239748
[TBL] [Abstract][Full Text] [Related]
15. Differences in Insulin Sensitivity, Secretion, and the Metabolic Clearance Rate of Glucose in Newly Diagnosed Type 2 Diabetes Mellitus Patients: The Influences of Body Mass Index and Fatty Liver.
Xie Y; Li S; Chen R; He R; Qian L; Zou J; Luo Y; Zhang Y; Ji M; Liu Y
Metab Syndr Relat Disord; 2022 Oct; 20(8):451-458. PubMed ID: 36260098
[No Abstract] [Full Text] [Related]
16. Citrus flavonoids and lipid metabolism.
Assini JM; Mulvihill EE; Huff MW
Curr Opin Lipidol; 2013 Feb; 24(1):34-40. PubMed ID: 23254473
[TBL] [Abstract][Full Text] [Related]
17. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease.
Ziolkowska S; Binienda A; Jabłkowski M; Szemraj J; Czarny P
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681787
[TBL] [Abstract][Full Text] [Related]
18. Naringenin attenuates hepatitis B virus X protein-induced hepatic steatosis.
Lin HJ; Ku KL; Lin IH; Yeh CC
BMC Complement Altern Med; 2017 Nov; 17(1):505. PubMed ID: 29183361
[TBL] [Abstract][Full Text] [Related]
19. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.
Mulvihill EE; Allister EM; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Markle JM; Hegele RA; Huff MW
Diabetes; 2009 Oct; 58(10):2198-210. PubMed ID: 19592617
[TBL] [Abstract][Full Text] [Related]
20. Naringenin suppresses macrophage infiltration into adipose tissue in an early phase of high-fat diet-induced obesity.
Yoshida H; Watanabe H; Ishida A; Watanabe W; Narumi K; Atsumi T; Sugita C; Kurokawa M
Biochem Biophys Res Commun; 2014 Nov; 454(1):95-101. PubMed ID: 25450363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
